Strategic information is everyone’s business: perspectives from an international stakeholder meeting to enhance strategic information data along the HIV Cascade for people who inject drugs by Richard D. Pierce et al.
COMMENTARY Open Access
Strategic information is everyone’s business:
perspectives from an international stakeholder
meeting to enhance strategic information data
along the HIV Cascade for people who inject
drugs
Richard D. Pierce1, Jennifer Hegle2, Keith Sabin3, Edo Agustian4, Lisa G. Johnston5, Stephen Mills6
and Catherine S. Todd6*
Abstract
People who inject drugs (PWID) are at increased HIV transmission risk because of unsafe injecting practices and a host
of other individual, network, and structural factors. Thus, PWID have a great need for services within the Cascade of HIV
prevention, diagnosis, care, and treatment (HIV Cascade). Yet the systems that monitor their progress through the
Cascade are often lacking. Subsequently, fewer reliable data are available to guide programs targeting this key
population (KP). Programmatic data, which are helpful in tracking PWID through the Cascade, also are limited because
not all countries have harm reduction programming from which to estimate Cascade indicators. Also, due to stigma
and the illegal nature of drug use, PWID may not disclose their drug use behavior or HIV status when accessing services.
Consequently, PWID appear to have low HIV testing rates and, for those living with HIV, lower access to health services
and lower viral suppression rates than do other KP groups. This commentary, based on outcomes from an international
stakeholder meeting, identifies data gaps and proposes solutions to strengthen strategic information (SI), the systematic
collection, analysis, and dissemination of information, to optimize HIV prevention, care, and treatment programming for
PWID.




Injecting drug use is the most efficient mode of transmit-
ting HIV and viral hepatitis, and people who inject drugs
(PWID) are disproportionately affected by HIV because of
behaviors influenced by individual, network, and struc-
tural factors [1–3]. However, stigma and criminalization
of drug use and the attendant difficulty measuring these
factors confound efforts to compile much-needed HIV ep-
idemiologic data among PWID, including prevalence, test-
ing frequency, and, for PWID diagnosed with HIV,
transition into care and treatment retention [4–6]. This
lack of strategic information (SI)—defined as the systematic
collection, analysis, and dissemination of information to
optimize programming—hinders our ability to design ef-
fective programming interventions for, and address the
needs of, PWID. Deficiencies in SI and attendant weaker
programming will likely impede progress toward the
UNAIDS “90-90-90” targets by 2020, which are that 90 %
of all people living with HIV (PLHIV) will know their HIV
status, 90 % of all PLHIV will receive sustained antiretro-
viral therapy (ART), and 90 % of those receiving ART will
have achieved viral suppression [7].
To identify gaps in this process and recommend ap-
proaches to optimize SI collection and use for PWID
programming, the meeting “People Who Inject Drugs:
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Strategic Information to Reach the 90-90-90: A Global
Conversation to Review the Evidence And Recommend
Improved SI Practices to Inform The Cascade” was con-
vened. This commentary conveys key meeting points and
recommendations from a variety of perspectives, with the
goal of rectifying SI deficiencies, identifying innovative
data-driven programming approaches, and integrating re-
spectful practices into PWID SI and programmatic activ-
ities to optimize achievement of 90-90-90 goals for PWID.
Setting
Fifty-one subject matter experts in PWID advocacy,
harm reduction, and HIV surveillance and monitor-
ing met in Bangkok, Thailand, on May 15, 2015. The
meeting was hosted by LINKAGES, a global project
funded by the United States Agency for International
Development (USAID) and the President’s Emergency
Plan For AIDS Relief (PEPFAR) and dedicated to key pop-
ulations (KPs)—PWID, sex workers, men who have sex
with men, and transgender people [8]. This meeting was a
satellite meeting to the UNAIDS and WHO-convened
Third Global HIV Surveillance Consultation (May 12–14)
and all attendees were invited, as were harm reduction im-
plementers and PWID advocacy group representatives
identified by meeting organizers and LINKAGES technical
staff. Attendees represented a wide variety of groups,
including donor organizations (e.g., Global Fund to Fight
AIDS, Tuberculosis and Malaria, USAID), United Nations
agencies (UNAIDS, UNODC), non-government organiza-
tions, harm reduction-implementing organizations, aca-
demia, and national, regional, and global PWID advocacy
groups; most of the latter two groups were from Asia.
The interactive meeting comprised a review of gaps in
epidemiologic data among PWID and a formal presenta-
tion on SI limitations and population size estimate ap-
proaches, followed by panel discussions addressing (1)
PWID community involvement in SI collection and use
and (2) challenges/solutions to indicator choices and use
of programmatic data to inform indicators from an imple-
menters’ perspective. Meeting participants then divided
into four groups to discuss gaps and potential solutions to
SI content relevant to PWID (Table 1). The proceedings
were transcribed, and main points are summarized in this
article; no other documents were produced.
Controversies and gaps in HIV epidemiology among
PWID
Current global HIV prevalence data among PWID belie
substantial variance in sub-epidemics and in national
reporting approaches. Many countries do not submit
single national HIV prevalence figures for some or all
KPs, and some countries do not have updated data for
international analysis [9]. National prevalence data are
typically gathered from integrated bio-behavioral surveys
(IBBS), which are conducted in areas, usually large cities,
with known high rates of drug use. Other methods of
obtaining prevalence data include sentinel surveillance
and case reporting. As a result, these estimates may not
reflect the entire country or account for emerging epi-
demics. For example, the Kenyan IBBS in Nairobi and
Mombasa, cities with documented large drug user popu-
lations, reported HIV prevalence of 30 % among PWID.
However, in Kisumu, Kenya, which was not included in
national data collection, ethnographic research detected
a new, hidden population of PWID among whom HIV
prevalence was 19 % [10]. Therefore, it may not be
wholly accurate to rely solely on national-level data for
HIV prevalence among PWID or to make programming
and funding decisions without considering local and re-
gional trends in HIV prevalence and risk behaviors.
Similar issues are present for estimating PWID popu-
lation sizes, as regional and global estimates are im-
pacted by outdated or insufficient data. Forty countries
included in a 2014 global harm reduction assessment
did not provide national PWID population size estimates
within the last 8 years. By region, Eurasia was found to
have some of the strongest reporting and service delivery
programs, while, in Asia, 60 % of 25 reporting countries
submitted outdated figures, in some cases from 2001
[11]. This lack of recent data raises two concerns: that
neither meaningful HIV data collection on PWID nor
HIV prevention among PWID are political priorities
within these countries.
Choosing the best SI approach
Data collection methods to inform HIV programming
for PWID must be scientifically robust and context-
and population-appropriate. For example, locations
with small PWID populations, but potentially explosive
epidemics, are not well represented within IBBS. Fur-
ther, specific sub-populations of PWID, such as adoles-
cent and young PWID and females who inject drugs
are poorly represented within IBBS, even when using
chain-referral sampling methods. At the meeting, pre-
senters suggested conducting targeted surveys for
these vulnerable groups as well as including youth in
future adult studies by broadening age eligibility.
Though parental consent is necessary in many settings,
many countries are reducing the age requiring parental
consent for HIV testing and counseling, which could
open an effective avenue for countries to allow surveys
among adolescent KPs.
Female PWID also are often under-represented in some
SI approaches, such as surveys using respondent-driven
sampling (RDS). Women who inject drugs tend not to
have robust social networks, compared to men, and are
often excluded from analysis. As a result, little or no data
are collected about the magnitude of their HIV burden.
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In Vietnam, females were excluded in both sentinel sur-
veys and the 2012 IBBS due to sampling barriers,
and in Myanmar, RDS referral chains often
terminated at female participants. New strategies, or
perhaps more qualitative data, are thus needed to
collect actionable SI from women who inject drugs.
Table 1 Key strategic information gaps and proposed solutions for people who inject drugs identified within small group discussion
Group
number
Discussion topic Identified gaps Recommendations
1 Identifying, reaching, and testing
people who inject drugs (PWID)
● Populations of females who inject drugs
are underrepresented
● Programs should also be able to identify emerging risk
behaviors; they could gather information in both formal
and informal ways
● Population size estimates are not accurate ● Separate Cascades would allow data collectors to
capture subgroups within the larger PWID groups
● Delays in estimating population size within
surveys are slowing testing and uptake
because services are not provided where
PWID are located
● Use programs more strategically for data collection
along the Cascade
● Reach of programs depends on political
and legal environments. There is limited
information from closed settings, such as
prisons
● Use peer educators and PWID drop-in centers for care
and support
● Link with hospitals and other treatment sites for
referrals
2 Testing PWID and enrolling
them in care and treatment
● Limited data on how many PWID living
with HIV are actually in care and treatment
● Community-based testing should be scaled up
● Lack of linkages between PWID-focused
programming and HIV care and treatment
programming
● Scale up the use of HIV rapid tests using oral fluid
samples, which are more convenient and preferable
to most people
● Stigma and discrimination prevent
members of key populations from seeking
testing services
● Periodically test MMT clients for HIV when they receive
their methadone
● Challenges in ensuring anonymity when
tracking people along the Cascade
● Use a mix of different approaches, different entry points
into the Cascade in SI collection
● The testing service delivery model could
be more targeted
● Mix program and surveillance, community support, and
case management
3 Gaps in strategic information;
challenges and solutions for
retention of PWIDs in care and
treatment
● Uneven coverage of drug dependence
treatment and OST
● Integrated MMT and ART services
● Uneven coverage of peer/family/social
support
● Establish models of peer-administered ART delivery or
limited peer-peer interventions to improve adherence
● Difficult to disaggregate data by risk
behavior or key population group
● Ask clinicians to collect risk group/behavior status
● Information by risk group is not used to
inform the Cascade
● In IBBS/surveys, include biomarkers for ART use in
testing and data collection to inform ART uptake and
viral suppression pillars within the Cascade
● Lack of data on reasons for loss to follow-
up and on mortality
4 Respectful approaches to data
collection
● “Respectful” can mean different things to
different people
● Protect PWID identities through encryption and unique
identifier codes
● There are different clearance requirements
for different countries
● Adopt the human rights framework for SI activities
● The meaning of community can vary, and
this can challenge how PWID
communities are integrated in data
collection
● Consider the community-based participatory research
framework
● It can be difficult to guarantee anonymity ● Ensure that services are available for the kinds of
problems that are being investigated. For example,
needle distribution and MMT programming should be
identified before initiating a study that intends to refer
participants to these services
upon request
● How to get people to disclose behaviors/
practices that are criminalized
● Require funders of research to accept responsibility for
guaranteeing anonymity
Pierce et al. Harm Reduction Journal  (2015) 12:41 Page 3 of 6
Case reporting or collection of harm reduction pro-
grammatic data may be more feasible as it allows for the
collection of local level data that are eventually reported
to national-level health officials [12]. Methodologic
questions to consider when selecting an SI approach are:
“What is the definition of PWID and how does this
change by context?” “Will it be regional or ‘hot-spot-
based’ within countries?” and “What are the data sources
and are data quality and focus appropriate?” However,
responses to these diverse HIV epidemics require de-
nominators to measure the number of people living with
HIV for a given KP, a pillar in the HIV Cascade. One
way to estimate these denominators, as well as inform
other Cascade components, is to ask participants about
their HIV status in IBBS or similar surveys [13]. Consist-
ent concerns collecting SI data include sensitivity in ask-
ing people about their drug use and HIV status and
assuring confidentiality in reporting them, especially
given the potential to further criminalize and stigmatize
this population.
To reach 90-90-90 goals, SI systems for PWID need to
move to a “treatment-oriented” approach, increasing the
value of case-based reporting and following cases
through the HIV Cascade. Case-based reporting raises
confidentiality concerns as reporting requires following
individuals “through the system” and necessitates the
use of unique identifiers. Another option for obtaining
data for monitoring the HIV Cascade is to use program-
matic harm reduction data. However, program data does
not perfectly overlap with HIV Cascade indicators; for
example, HIV testing may occur within harm reduction
programs, but care and treatment services are provided
at separate sites with no formal data linkage to allow
follow-up through the Cascade. Double counting is also
an issue, which could be overcome by using unique
identifiers and recall of last testing site and date, with at-
tendant confidentiality concerns.
Collaborative approaches to integrating PWID in SI data
selection and collection
Within the “90-90-90” initiative, respect for human rights is
prominent—including involvement of KP groups in collect-
ing SI. PWID are the best resource for learning how to pro-
vide services to peers, and their involvement in data
collection is critical for ensuring a rights-based approach.
Based on their personal experience with criminalization and
stigma associated with drug use and further HIV-associated
stigma, PWID advocacy group representatives at the meeting
recommended that they be treated as partners in, rather than
just subjects of, research and SI data collection.
One way to ensure collaboration is to improve the cap-
acity of community-based, constituency-led organizations
to: engage in survey data collection, analysis, and dissemin-
ation; documentation; and monitoring and evaluation. A
successful example of this principle in practice is the
Persaudaraan Korban Napza Indonesia (PKNI)/Indonesian
Drug User Network. Beginning in 2007, PKNI, in col-
laboration with Oxford University, initiated Perempuan
Bersuara/“Women Speak Out,” a cross-sectional study
among approximately 700 females who inject drugs to
investigate factors associated with HIV risk among this
subgroup. PKNI established a community advisory group
comprising females who inject drugs to inform question-
naire design and guide ethical and operational study
aspects. The community-led team received ongoing cap-
acity building in research methods and data interpretation
from researchers, allowing them to develop marketable
skills and knowledge while playing a significant role in the
study’s implementation. This collaborative approach
resulted in a strong sense of community ownership of the
research and active participation from female respondents
in the project.
Criminalization of drug use is a major barrier to
collaboration with PWID. In Indonesia, for example, the
inclusion of PWID in SI collection is affected by a new
“War on Drugs.” Between 2014 and 2015 in Jakarta,
Bogor, and Bandung, community interviewers reported
harassment by National Narcotics Board officers and the
police, including raids, random urine testing, and arrest
threats during interviews. Such incidents led to lower
recruitment rates because of increased distrust and fear
by participants of providing information to researchers,
potentially resulting in reporting bias and less reliable
outcomes.
Novel models for improved SI collection and utilization
Capturing data to inform all Cascade indicators is challen-
ging and involves aggregation of clinical data up to the na-
tional level. This requires a mechanism for centralization
of data and consistency between data collection methods
across multiple programs. Two supply-side intervention
models to improve HIV testing uptake, diagnosis, and en-
rollment in care, specifically through increasing numbers
of PWID reached and tested, were presented from
Vietnam. In urban areas, the “Fansipan Challenge” model
recruited opiate substitution therapy clients, most of
whom inject, to bring friends or sexual partners for HIV
testing, and those testing positive to be enrolled in care
and treatment. This model rewards clients for each re-
ferral completing testing and subsequent referrals with
points and phone credit, structured as a contest to
climb Fansipan, Vietnam’s highest mountain [14]. For
rural areas, a direct referral model was tested in moun-
tainous provinces near the Lao border, where drug traf-
ficking and injecting use are common and care and
treatment commensurately low. This model offers ham-
let health worker incentives for successful referral for
mobile and facility-based HIV counseling and testing,
Pierce et al. Harm Reduction Journal  (2015) 12:41 Page 4 of 6
identification of HIV-positive individuals, and re-engaging
known HIV patients who were lost to care. In both
models, unique identifiers were used to track individuals
across the HIV Cascade, and questionnaires included more
questions (picture-based) on high-risk behaviors to pro-
vide meaningful SI contributions.
Scaling up successful program models and the accom-
panying SI concerns were also discussed. One panelist
described the transition of harm reduction programming
from small programs operated by civil society organiza-
tions to implementation of the same model by state and
national government. While this transition is in process,
SI and operations research has identified gaps in quality
of care, through lack of or insufficient number of syrin-
ges received from needle and syringe distribution and
collection programs and low ART uptake among clients
living with HIV. This example of using SI to improve
service quality is directed toward creating public-private
partnerships and improving political will to provide
quality services and enhance 90-90-90 outcomes.
Small group discussions
This meeting also included four small group discussions
on gaps related to and recommendations for SI collec-
tion for four content areas. Table 1 summarizes key gaps
and recommendations. Topics assigned to each group
did not allow for frequent overlap in recommendations,
but several key themes were present from all groups.
These themes included the following: (1) the need for in-
tegration of Cascade indicators into PWID program-
ming, potentially with merged harm reduction and HIV
management services; (2) expanding the role of peers
within the PWID community to improve testing cover-
age; (3) linkages to and retention in care; and (4) re-
spectful SI collection and interpretation.
Conclusions
Reaching PWID populations for HIV prevention, diagno-
sis, and treatment and tracking them through the HIV
Cascade of services is challenging due to persistent barriers
from governments, society, and health systems. PWID are
highly stigmatized, criminalized, and hidden, posing sig-
nificant challenges to estimating their population sizes and
HIV prevalence and assessing their prevention, care, and
treatment needs. This meeting delineated these challenges
and sought consensus on ways to derive more accurate
data, identify data gaps related to service uptake along the
HIV Cascade, and outline SI methods to better monitor
and improve the prevention and treatment needs of PWID
to support 90-90-90 goals. One key output was consensus
around the need to use programmatic data, with the caveat
that PWID-centered programs must be held accountable
for reporting accuracy, potentially through assessments by
a third party. There was clear consensus on the need to in-
volve the PWID community in SI data collection.
Finally, participants agreed that harm reduction program
client confidentiality must be maintained and respected.
Linking data between harm reduction programs and HIV
care and treatment services is critical, and models utilizing
unique codes or other approaches that respect client ano-
nymity need to be piloted and expanded if successful. The
meeting concluded with final comments that SI must have
direct application to program utilization and improve-
ment, as the data are meant to serve the clients and com-
munity. The closing message from the meeting was that
“SI is everyone’s business,” reflected by the importance of
identifying the best surveillance methods and HIV preven-
tion, care, and treatment program monitoring for PWID
for filling the gaps in the HIV Cascade and realizing the
90-90-90 goal.
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